实用肝脏病杂志2013，Vol.16Issue(3)：232-234,3.DOI:10.3969/j.issn.1672-5069.2013.03.013
核苷(酸)类似物治疗慢性乙型肝炎部分应答后加用α干扰素继续治疗疗效分析
Serological response of interferon-alpha-1b boasting regimen after virological response to nucleoside analogue treatment in patients with chronic hepatitis B
林琪 1余雪平 1苏智军 1郭如意1
作者信息
- 1. 362000 福建省泉州市 福建医科大学附属泉州第一医院感染病科
- 折叠
摘要
Abstract
Objective To evaluate the serological response of interferon-alpha-1b (INF-α-1b)boasting regimen after virological response to nucleoside analogue treatment in patients with chronic hepatitis B (CHB).Methods 71 patients with HBeAg-positive CHB were selected,and they had had HBV DNA loss and alanine aminotransferase (ALT)normalization,but had had not HBeAg negativity to nucleoside analogue treatment.Thirtyeight patients were treated with nucleoside analogues they always received and INF-α-lb,while 33 patients continued nucleoside analogues for 48 weeks.Results At the end of 36 weeks of treatment,the negative rate of serum HBeAg in combination group was significantly higher than that in nucleoside group (36.8％ vs.15.2％,P=0.039);At 48 weeks,the negative rate of serum HBeAg (42.1％)and HBeAg/anti-HBe seroconversion rate (36.8％) were significantly higher in the former group than those (18.2％ and 15.2％,respectively,P=0.030 and 0.039) in the latter;There were no ALT and HBV DNA fluctuation and obvious adverse reactions in the two groups.Conclusion IFN-α might rescue the nucleoside analogues therapy to improve HBeAg/anti-HBe seroconversion rate.关键词
慢性乙型肝炎/核苷(酸)类似物/干扰素/HBeAg血清转换Key words
Hepatitis B/Nucleoside analogues/ Interferon-α/ HBeAg/anti-HBe seroconversion引用本文复制引用
林琪,余雪平,苏智军,郭如意..核苷(酸)类似物治疗慢性乙型肝炎部分应答后加用α干扰素继续治疗疗效分析[J].实用肝脏病杂志,2013,16(3):232-234,3.
